<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>国广有话说 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-13T13:32:16+08:00</updated>
  <subtitle>立足于客观公正，挖掘发现医药企业价值投资机会</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>医药企稳后，2021年战略性配置高端制造！【东吴医药朱国广团队|1213周报】</title>
    <updated>2020-12-13T12:29:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/GHUF4vJteZd7SJpsdO2-_g</id>
    <link href="https://mp.weixin.qq.com/s/GHUF4vJteZd7SJpsdO2-_g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>万泰生物（603392）：止于至善的基因工程技术领跑者【东吴医药朱国广团队】</title>
    <updated>2020-12-07T18:16:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/MjjeiAwvIcrBLsQUyKkpjw</id>
    <link href="https://mp.weixin.qq.com/s/MjjeiAwvIcrBLsQUyKkpjw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021年为何战略性重视医药的“芯片”原料药资产？【东吴医药朱国广团队|1204周报】</title>
    <updated>2020-12-06T15:11:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/t3wiugd2s_VUqBMItxHlSQ</id>
    <link href="https://mp.weixin.qq.com/s/t3wiugd2s_VUqBMItxHlSQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>器械集采扩面，哪类公司方能最终胜出？【东吴医药朱国广团队|1127周报】</title>
    <updated>2020-11-29T16:31:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/gA2oumAxCXf_IaDgU_DxIw</id>
    <link href="https://mp.weixin.qq.com/s/gA2oumAxCXf_IaDgU_DxIw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“横看成岭侧成峰”——“秒懂”全球创新药系列研究之靶点掘金（第04期：CDK4/6）【东吴医药朱国广团队】</title>
    <updated>2020-11-26T19:59:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/RMrHhTP0tAKb_8mZvRW02g</id>
    <link href="https://mp.weixin.qq.com/s/RMrHhTP0tAKb_8mZvRW02g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最强医药股的补跌说明什么？【东吴医药朱国广团队|1122周报】</title>
    <updated>2020-11-22T15:58:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/-0mIZ6_J9iSjLJHYgRUX6g</id>
    <link href="https://mp.weixin.qq.com/s/-0mIZ6_J9iSjLJHYgRUX6g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新药行业动态追踪系列研究之2020医保谈判猜想（第01期：政策点拨）【东吴医药朱国广团队】</title>
    <updated>2020-11-18T14:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/Y7oTnYR53A4Qdmk0cvchIw</id>
    <link href="https://mp.weixin.qq.com/s/Y7oTnYR53A4Qdmk0cvchIw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>南微医学(688029)事件点评：股权激励方案发布，彰显公司未来信心【东吴医药朱国广团队】</title>
    <updated>2020-11-17T10:52:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-17:/s/eehdcPdfTonhH9gZ4gi0oQ</id>
    <link href="https://mp.weixin.qq.com/s/eehdcPdfTonhH9gZ4gi0oQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>爱美客（300896）事件点评：利拉鲁肽临床试验获批，减肥减重产品取得积极进展【东吴医药&amp;社服零售】</title>
    <updated>2020-11-16T14:55:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/JgIxx5rXQ7MTxRmRtj8yqQ</id>
    <link href="https://mp.weixin.qq.com/s/JgIxx5rXQ7MTxRmRtj8yqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Q4为何是医药战略性建仓最佳时机？【东吴医药朱国广团队|1115周报】</title>
    <updated>2020-11-15T13:37:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/3v9QX4VzgzFVuWnMvD1HRA</id>
    <link href="https://mp.weixin.qq.com/s/3v9QX4VzgzFVuWnMvD1HRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>